Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Cramer's 'Mad Money' Recap: China and U.S. Stocks

Tickers in this article: AAPL ALU AVNR CAT CIEN CMI CSCO CYN DVA ETN F FIG FNSR GE GM HCI JDSU JOY NES PRI PVH RPTP SGEN
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- If China and Europe can take our markets lower, why can't they take them higher as well? That's what Jim Cramer asked "Mad Money" viewers Monday.

Cramer said that after years of dragging U.S. stocks lower, the evidence is mounting that a turn is at hand overseas, and that should be great news for U.S. stocks.

The media may be focused on Syria and the Federal Reserve, but Cramer said today's market rally was all about an improving global economy. He said many investors just don't realize many Chinese exports are sold in Europe. With Europe making a slow but steady turn for the better, China will be buoyed as well.

Cramer said he was dead wrong in 2011 when he went bullish on Ford , a stock he owns for his charitable trust, Action Alerts PLUS. However, it's not unrealistic to think the automaker could now surpass its 2011 highs of $18 a shares now that Europe has actually become the tailwind he expected.

That's certainly what happened with Eaton , another Action Alerts holding, as that stock is almost back to where it was when it disappointed last quarter.

Whether it's Caterpillar or Cummins or even Apple , yet another portfolio holding, all of these stocks have Chinese exposure that's being helped by a rising Europe.

Cramer said that when Joy Global delivers hideous guidance and shares rally thereafter, well, "that smells like a bottom." He said that everything from General Motors to General Electric , from the rails to the banks could all be in on this move. Investors just need to pick the right stocks.

Executive Decision: Clay Siegall

In the "Executive Decision" segment, Cramer sat down with Dr. Clay Siegall, chairman, president and CEO of Seattle Genetics , one of the many biotech firms leading the charge against cancer. Shares of Seattle Genetics have risen over 88% since Cramer last spoke with Siegall in December.

Siegall said Seattle Genetics currently has over 20 clinical trials in process, both developing new drugs and expanding the uses and indications of their current ones. He said his company's treatments are not providing incremental improvements to the way cancer is being treated, they're saving lives and providing real benefits to a lot of patients.